Integrative transcriptomic meta-analysis of Parkinson's disease and depression identifies NAMPT as a potential blood biomarker for de novo Parkinson's disease.
Emerging research indicates that depression could be one of the earliest prodromal symptoms or risk factors associated with the pathogenesis of Parkinson's disease (PD), the second most common neurodegenerative disorder worldwide, but the mechanisms underlying the association between both diseases remains unknown. Understanding the molecular networks linking these diseases could facilitate the discovery of novel diagnostic and therapeutics. Transcriptomic meta-analysis and network analysis of blood microarrays from untreated patients with PD and depression identified genes enriched in pathways related to the immune system, metabolism of lipids, glucose, fatty acids, nicotinamide, lysosome, insulin signaling and type 1 diabetes. Nicotinamide phosphoribosyltransferase (NAMPT), an adipokine that plays a role in lipid and glucose metabolism, was identified as the most significant dysregulated gene. Relative abundance of NAMPT was upregulated in blood of 99 early stage and drug-naïve PD patients compared to 101 healthy controls (HC) nested in the cross-sectional Parkinson's Progression Markers Initiative (PPMI). Thus, here we demonstrate that shared molecular networks between PD and depression provide an additional source of biologically relevant biomarkers. Evaluation of NAMPT in a larger prospective longitudinal study including samples from other neurodegenerative diseases, and patients at risk of PD is warranted.
The Cellular and Molecular Pharmacology Department, The Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA.
Jose A
JA
Santiago
The Cellular and Molecular Pharmacology Department, The Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA.
Alyssa M
AM
Littlefield
The Cellular and Molecular Pharmacology Department, The Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA.
Judith A
JA
Potashkin
Prog Neurobiol. 2011 Dec;95(4):629-35
21930184
Curr Opin Pharmacol. 2016 Feb;26:102-9
26609801
Proc Natl Acad Sci U S A. 2015 Jan 27;112(4):1167-72
25092317
Mol Psychiatry. 2013 Mar;18(3):332-9
22158016
PLoS One. 2010 Sep 29;5(9):null
20927376
Neurology. 2013 Oct 22;81(17):1538-44
24089392
Oncotarget. 2016 Apr 5;7(14 ):17410-4
27007159
PLoS One. 2013 Dec 20;8(12):e83940
24376773
Trends Mol Med. 2013 Mar;19(3):187-96
23318001
J Neurol. 2003 Dec;250(12):1453-5
14673578
Mov Disord. 2013 Oct;28(12):1724-7
24108702
Ann Neurol. 2011 Apr;69(4):655-63
21520231
Neurology. 2002 May 28;58(10):1501-4
12034786
Mol Psychiatry. 2016 Jul;21(7):903-9
27021822
Exp Neurol. 2014 Jan;251:22-9
24220636
PLoS One. 2014 Oct 03;9(10):e109042
25279756
J Neuroimmunol. 2014 Aug 15;273(1-2):8-21
24969117
Adv Neurol. 1990;53:163-6
2239456
Nat Rev Neurol. 2011 Dec 26;8(1):35-47
22198405
BMC Res Notes. 2011 Sep 06;4:324
21896205
Mov Disord. 2010 Jul 15;25(9):1157-62
20310050
Acta Neurol Scand. 2006 Apr;113(4):211-20
16542159
Acta Psychiatr Scand. 2001 Nov;104(5):380-6
11722320
Biomed Res Int. 2014;2014:718732
24804238
Mov Disord. 2014 Apr;29(4):550-5
24347522
Neurology. 2015 Jun 16;84(24):2422-9
25995056
Transl Psychiatry. 2014 Sep 16;4:e442
25226551
Acta Psychiatr Scand. 2002 Sep;106(3):202-11
12197858
Biol Psychiatry. 2010 Mar 1;67(5):446-57
20015486
Neurobiol Dis. 2012 Jun;46(3):527-52
22192366
Neurobiol Dis. 2014 Dec;72 Pt A:84-91
24718034
Front Neurol. 2014 Sep 25;5:188
25309508
Mol Psychiatry. 2016 Oct;21(10):1358-65
26552591
Am J Med Genet B Neuropsychiatr Genet. 2011 Jun;156B(4):382-92
21438146
Mol Med Rep. 2016 May;13(5):4058-64
27035562
Lancet Neurol. 2015 Oct;14 (10 ):1002-9
26271532
Nucleic Acids Res. 2010 Jul;38(Web Server issue):W214-20
20576703
Mov Disord. 2003 Apr;18(4):414-8
12671948
Science. 2005 Jan 21;307(5708):426-30
15604363
J Neurol. 2013 Feb;260(2):438-44
22911513
Laryngoscope. 1984 Feb;94(2 Pt 1):176-8
6694486
Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):2257-62
25646437
PLoS One. 2015 Nov 13;10 (11):e0142582
26566043
J Clin Psychiatry. 2015 Feb;76(2):e199-206
25742207
Mov Disord. 2007 Jun 15;22(8):1077-92
17394234
Trends Mol Med. 2013 Mar;19(3):176-86
23375873
Brain. 2015 Sep;138(Pt 9):2659-71
26220939
BMC Genomics. 2015 Oct 28;16:876
26510930
Neurogenetics. 2015 Oct;16(4):245-63
25980689
Mov Disord. 2000 Jul;15(4):669-77
10928577
Neurobiol Aging. 2003 Mar-Apr;24(2):197-211
12498954
Trends Mol Med. 2014 Dec;20(12):694-703
25455073
Mov Disord. 2015 Oct;30(12 ):1648-56
26207725
Nat Rev Endocrinol. 2015 Sep;11(9):535-46
26215259
PLoS One. 2012;7(8):e43595
22952715
Neuroimmunomodulation. 2014;21(2-3):88-94
24557040
Neuron. 2003 Sep 11;39(6):889-909
12971891